These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31811290)

  • 21. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.
    Li X; Chan NS; Tam AW; Hung IFN; Chan EW
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1801-1809. PubMed ID: 28516201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years.
    Barnett MJ; Frank J; Wehring H; Newland B; VonMuenster S; Kumbera P; Halterman T; Perry PJ
    J Manag Care Pharm; 2009; 15(1):18-31. PubMed ID: 19125547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S;
    J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain.
    Turnes J; Domínguez-Hernández R; Casado MÁ
    Rev Esp Enferm Dig; 2017 Dec; 109(12):809-817. PubMed ID: 29152988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection.
    Ottman AA; Townsend ML; Hashem MG; DiMondi VP; Britt RB
    Ann Pharmacother; 2018 Aug; 52(8):763-768. PubMed ID: 29577765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics.
    Naidjate SS; Zullo AR; Dapaah-Afriyie R; Hersey ML; Marshall BDL; Winkler RM; Berard-Collins C
    Am J Health Syst Pharm; 2019 May; 76(10):646-653. PubMed ID: 30873537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C.
    Wade AJ; McCormack A; Roder C; McDonald K; Davies M; Scott N; Wardrop M; Athan E; Hellard ME
    J Viral Hepat; 2018 Sep; 25(9):1089-1098. PubMed ID: 29660212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of the Pharmaceutical Care Management Model of Hepatitis C Medications on the Cost at Health Insurance Level.
    Almahdi FB; Hashim AH; Albaba EAM; Salih ON; Alkasam RJ; Mosli MH; Alsulaimani AF
    Value Health Reg Issues; 2020 May; 21():230-237. PubMed ID: 32334165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
    Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
    Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
    J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
    Chhatwal J; He T; Hur C; Lopez-Olivo MA
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population.
    Mitra D; Davis KL; Beam C; Medjedovic J; Rustgi V
    Value Health; 2010; 13(4):479-86. PubMed ID: 20102555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost.
    Keast SL; Holderread B; Cothran T; Skrepnek GH
    J Am Pharm Assoc (2003); 2018; 58(5):485-491. PubMed ID: 30033127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution.
    Gauthier TP; Moreira E; Chan C; Cabrera A; Toro M; Carrasquillo MZ; Corentin M; Sherman EM
    J Am Pharm Assoc (2003); 2016; 56(6):670-676. PubMed ID: 27667501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system.
    Altavela JL; Jones MK; Ritter M
    J Manag Care Pharm; 2008; 14(9):831-43. PubMed ID: 19006440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.